13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001940272
Total reported value
$2.2B
$2.2B
203 檔
10.6%
As reported in its official Q2 2025 Form 13F filing, ADAR1 Capital Management, LLC's tracked investment portfolio stood at $2.2B with 203 total positions.
During Q2 2025, ADAR1 Capital Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
Showing top 200 holdings (of 203 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | KROS | Keros Therapeutics Inc | Stock-Other | 11.03% | +0.06% | +262.56% | |
| 2 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 8.04% | -0.78% | +0.89% | |
| 3 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 5.99% | +2.36% | — | |
| 4 | BOXX | Alpha Architect 1-3 Mnth Box | ETF-Other | 5.83% | -0.50% | — | |
| 5 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 4.56% | +1.35% | -9.61% | |
| 6 | ABVX | Abivax Sa-adr | Stock-Other | 3.60% | +1.85% | +38.97% | |
| 7 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 3.35% | -0.25% | -44.28% | |
| 8 | PRTA | Prothena Corporation plc | Stock-Other | 3.14% | -0.20% | — | |
| 9 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.95% | -0.66% | +48.99% | |
| 10 | CGON | Cg Oncology Inc | Stock-Other | 2.09% | -0.35% | +73.75% | |
| 11 | BIL | Ss Spdr Bb 1-3m T-bill ETF | ETF-Gov Bonds | 1.91% | -0.16% | — | |
| 12 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.72% | +0.19% | -23.55% | |
| 13 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 1.53% | +0.04% | — | |
| 14 | SEPN | Septerna Inc | Stock-Other | 1.37% | -0.10% | +17.53% | |
| 15 | ABUS | Arbutus Biopharma CORP | Stock-Other | 1.34% | -0.55% | +50.38% | |
| 16 | ETNBGBP | 89bio Inc | Stock-Other | 1.32% | — | +8.92% | |
| 17 | IMVT | Immunovant Inc | Stock-Other | 1.31% | +0.19% | -44.77% | |
| 18 | SVRA | Savara Inc | Stock-Other | 1.26% | -0.07% | +164.70% | |
| 19 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.25% | -0.32% | +103.46% | |
| 20 | BIOA | Bioage Labs Inc | Stock-Other | 1.23% | -0.14% | EXIT | |
| 21 | ✓ | Stock-Other | 1.22% | +0.02% | — | ||
| 22 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 1.18% | -0.38% | -18.11% | |
| 23 | JANX | Janux Therapeutics Inc | Stock-Other | 1.16% | +0.06% | -21.90% | |
| 24 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 1.07% | -0.36% | +6451.18% | |
| 25 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 1.07% | +0.17% | +182.27% | |
| 26 | SG7 | Sage Therapeutics Inc | Stock-Other | 1.01% | — | -2.81% | |
| 27 | RAPT | Rapt Therapeutics Inc | Stock-Other | 0.96% | — | — | |
| 28 | YCY-UN | AA Mission Acquisition Corp. II | Stock-Other | 0.92% | — | — | |
| 29 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.90% | -0.11% | — | |
| 30 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 0.89% | -0.05% | -33.96% | |
| 31 | ✓ | Stock-Other | 0.84% | -0.06% | — | ||
| 32 | ✓ | Verve Therapeutics Inc | Stock-Other | 0.81% | — | — | |
| 33 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.76% | -0.02% | -24.28% | |
| 34 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.72% | — | -5.77% | |
| 35 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.70% | +0.26% | +115.84% | |
| 36 | SHY | Ishares 1-3 Year Treasury Bo | ETF-Gov Bonds | 0.68% | — | -48.39% | |
| 37 | RZLT | Rezolute Inc | Stock-Other | 0.68% | — | -11.36% | |
| 38 | BBIO 2.25 02-01-29Bond | Bridgebio Pharma Inc | Bond | 0.64% | -0.06% | — | |
| 39 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.63% | +0.12% | +14.69% | |
| 40 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.60% | -0.09% | EXIT | |
| 41 | MNPR | Monopar Therapeutics Inc | Stock-Other | 0.55% | +0.07% | +0.20% | |
| 42 | ARDX | Ardelyx Inc | Stock-Other | 0.55% | -0.01% | +86.48% | |
| 43 | ✓ | Third Harmonic Bio Inc | Stock-Other | 0.52% | — | +522.87% | |
| 44 | PCVX | Vaxcyte Inc | Stock-Other | 0.49% | -0.50% | +665.88% | |
| 45 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 0.44% | -0.39% | +23.04% | |
| 46 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 0.41% | — | +42.25% | |
| 47 | BBIO 2.5 03-15-27Bond | Bridgebio Pharma Inc | Bond | 0.38% | -0.05% | — | |
| 48 | ALEC | Alector Inc | Stock-Other | 0.37% | +0.14% | +353.17% | |
| 49 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.37% | -0.35% | EXIT | |
| 50 | SMMT | Summit Therapeutics Inc | Stock-Other | 0.37% | +0.03% | +12.00% |
According to official SEC Form 13F filings, ADAR1 Capital Management, LLC reported a total U.S. public equity portfolio value of $2.2B across 203 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including KROS, PTGX, SPY) accounted for 10.6% of total reported equity market value during Q2 2025.
During Q2 2025, ADAR1 Capital Management, LLC's top holdings by market value included KROS (11.0%)、PTGX (8.0%)、SPY (6.0%). The largest single position, KROS, represented 11.0% of total portfolio value.
In Q2 2025, ADAR1 Capital Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.